Literature DB >> 17401177

Preparation and titration of CsCl-banded adenovirus stocks.

Ann E Tollefson1, Mohan Kuppuswamy, Elena V Shashkova, Konstantin Doronin, William S M Wold.   

Abstract

Adenovirus research often requires purified high-titer virus stocks and accurate virus titers for use in experiments. Accurate titers are important for quantitative, interpretable, and reproducible results. This is especially true when there are comparisons of different mutant viruses following infection. This chapter details the large-scale preparation of adenovirus (either replication-competent or replication-defective) in spinner cultures (e.g., KB, HeLa, or 293 cells). Protocols for harvesting cells and isolation of adenovirus by CsCl banding are presented. Methods for titering adenovirus by plaque assay are presented along with a discussion of how plaque assays can be used to determine the kinetics of cell killing and cytolysis by adenoviruses.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17401177     DOI: 10.1385/1-59745-166-5:223

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN: 1543-1894


  43 in total

1.  Mutations within the ADP (E3-11.6K) protein alter processing and localization of ADP and the kinetics of cell lysis of adenovirus-infected cells.

Authors:  Ann E Tollefson; Abraham Scaria; Baoling Ying; William S M Wold
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

2.  Optimized adenovirus-antibody complexes stimulate strong cellular and humoral immune responses against an encoded antigen in naive mice and those with preexisting immunity.

Authors:  Jin Huk Choi; Joe Dekker; Stephen C Schafer; Jobby John; Craig E Whitfill; Christopher S Petty; Eid E Haddad; Maria A Croyle
Journal:  Clin Vaccine Immunol       Date:  2011-11-16

3.  Identification of a previously unrecognized promoter that drives expression of the UXP transcription unit in the human adenovirus type 5 genome.

Authors:  Baoling Ying; Ann E Tollefson; William S M Wold
Journal:  J Virol       Date:  2010-08-25       Impact factor: 5.103

4.  Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors.

Authors:  Di Yu; Chuan Jin; Justyna Leja; Nadim Majdalani; Berith Nilsson; Fredrik Eriksson; Magnus Essand
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

5.  High temporal resolution imaging reveals endosomal membrane penetration and escape of adenoviruses in real time.

Authors:  Ruben Martinez; Andrew M Burrage; Christopher M Wiethoff; Harald Wodrich
Journal:  Methods Mol Biol       Date:  2013

6.  Adenovirus E3-6.7K protein is required in conjunction with the E3-RID protein complex for the internalization and degradation of TRAIL receptor 2.

Authors:  Drew L Lichtenstein; Konstantin Doronin; Karoly Toth; Mohan Kuppuswamy; William S M Wold; Ann E Tollefson
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

7.  Involvement of template-activating factor I/SET in transcription of adenovirus early genes as a positive-acting factor.

Authors:  Hirohito Haruki; Mitsuru Okuwaki; Makoto Miyagishi; Kazunari Taira; Kyosuke Nagata
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

8.  Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters.

Authors:  Debanjan Dhar; Jacqueline F Spencer; Karoly Toth; William S M Wold
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

9.  Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster model.

Authors:  Debanjan Dhar; Jacqueline F Spencer; Karoly Toth; William S M Wold
Journal:  Mol Ther       Date:  2009-07-14       Impact factor: 11.454

10.  Distinct domains in the adenovirus E3 RIDalpha protein are required for degradation of Fas and the epidermal growth factor receptor.

Authors:  Tom A Zanardi; Soonpin Yei; Drew L Lichtenstein; Ann E Tollefson; William S M Wold
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.